Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CCR2 | P41597 | 4/20 | 0.57 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422338 | 0.96 | MCL1 (0.62) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL29750342 | 0.92 | ALDH1A1 (0.64) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL7894118 | 0.92 | ALDH1A1 (0.64) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL13701158 | 0.87 | CCR2 (0.69) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL25145112 | 0.86 | MTNR1A (0.53) | MCL1ALDH1A1CYP1A2POLBCNR2 | |
| SCHEMBL6754206 | 0.86 | ALDH1A1 (0.59) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL29463267 | 0.84 | KDM4E (0.65) | MCL1CNR2MTNR1AMTNR1B | |
| SCHEMBL10757133 | 0.84 | ALDH1A1 (0.66) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL6682164 | 0.83 | ALDH1A1 (0.64) | MCL1ALDH1A1CYP1A2POLBCCR2 | |
| SCHEMBL2480710 | 0.83 | ALDH1A1 (0.57) | MCL1ALDH1A1CYP1A2POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | claimed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | claimed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | claimed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | MCL1 4652/4885ALDH1A1 494/4885CYP1A2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.